Ashwagandha Cognitive Performance Meta-analysis: What the Evidence Says

Quick Answer

Ashwagandha Cognitive Performance Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• For example,evaluated nine randomized controlled trials by meta-analysis, and found that the scores of Perceived Stress Questionnaire (PSS), Anxiety Score (HAS) and serum cortisol levels were significantly reduced, indicating that it has a significant anti-pressure effect. [Zhu XiaoLing (2026); evidence level 1]
• A study involving 80 healthy subjects aged 18-45&#160;years showed that, compared with the placebo group, the Ashwagandha-supplemented group significantly improved bench press and leg lift strength, arm circumference and chest circumference, thigh circumference, and maximum oxygen uptake (VOmax) (p < 0.05). [Zhu XiaoLing (2026); evidence level 1]
• These limitations have catalyzed an increased global focus on nutraceuticals and phytomedicines possessing multimodal biological activities that transcend mere monoamine reuptake inhibition. [Li Xikun (2026); evidence level 3]
• Unlike prior reviews that focus on individual herbs or broadly defined adaptogens, the present review integrates mechanistic, preclinical, and clinical evidence across these three agents to highlight their complementary rather than redundant actions. [Li Xikun (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For ashwagandha cognitive performance meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Zhu XiaoLing (2026). Effects of Withania somnifera (L.) Dunal (Ashwagandha) on cognitive and physical function in adults: a systematic review and meta-analysis. DOI: 10.3389/fphar.2026.1799467. PMCID: PMC13199302. PMID: 42199854. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13199302/
• Li Xikun (2026). Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders. DOI: 10.3389/fnut.2026.1762061. PMCID: PMC13017319. PMID: 41909050. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13017319/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.